Related Experiment Video
Updated: Aug 8, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
CAMPATH: from concept to clinic
1Sir William Dunn School of Pathology, University of Oxford, UK. herman.waldmann@path.ox.ac.uk
Abstract:
Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chronic lymphocyte leukaemia. Short-term therapy with alemtuzumab has demonstrated long-term benefit in a number of autoimmune conditions. This drug has the potential to facilitate recruitment of tolerance processes so enabling drug minimization in transplantation, autoimmune and hypersensitivity diseases.
More Related Videos
08:13Development and Implementation of a Multi-Disciplinary Technology Enhanced Care Pathway for Youth and Adults with Concussion
Published on: January 20, 2019
06:32Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation
Published on: July 14, 2023
Related Concept Videos
Gene Therapy
Patient-centered Care
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Discovery: Overview
Clinical Trials: Overview
Preclinical Development: Overview